A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1 second (FEV1) in patients with mild-to-moderate persistent atopic asthma
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2018
At a glance
- Drugs PBF 680 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Palobiofarma
- 15 Jun 2018 Status changed from planning to recruiting.
- 13 Apr 2018 New trial record
- 12 Apr 2018 According to a Palobiofarma media release, the company is planning to start this trial in the second quarter of 2018.